CXCL16 Orchestrates Adenosine A3 Receptor and MCP-1/CCL2 Activity to Protect Neurons from Excitotoxic Cell Death in the CNS

A role for chemokines as molecules mediating neuron-glia cross talk has emerged in recent years, both in physiological and pathological conditions. We demonstrate here for the first time that the chemokine CXCL16 and its unique receptor CXCR6 are functionally expressed in the CNS, and induce neuroprotection against excitotoxic damage due to excessive glutamate (Glu) exposure and oxygen glucose deprivation (OGD). In mice and rats we found that, to exert neuroprotection, CXCL16 requires the presence of extracellular adenosine (ADO), and that pharmacological or genetic inactivation of the ADO A3 receptor, A3R, prevents CXCL16 effect. In experiments with astrocytes cocultured with cxcr6gfp/gfp hippocampal cells, we demonstrate that CXCL16 acts directly on astrocytes to release soluble factors that are essential to mediate neuroprotection. In particular, we report that (1) upon stimulation with CXCL16 astrocytes release monocyte chemoattractant protein-1/CCL2 and (2) the neuroprotective effect of CXCL16 is reduced in the presence of neutralizing CCL2 antibody. In conclusion, we found that chemokine CXCL16 is able to mediate cross talk between astrocytes and neighboring neurons and, in pathological conditions such as excessive Glu or OGD exposure, is able to counteract neuronal cell death through an ADO-dependent chemokine-induced chemokine-release mechanism.

[1]  M. Rathbone,et al.  Mechanisms of apoptosis induced by purine nucleosides in astrocytes , 2002, Glia.

[2]  K. Biber,et al.  Adenosine A3 receptor‐induced CCL2 synthesis in cultured mouse astrocytes , 2004, Glia.

[3]  J. Berman,et al.  MCP‐1 (CCL2) protects human neurons and astrocytes from NMDA or HIV‐tat‐induced apoptosis , 2003, Journal of neurochemistry.

[4]  Catarina Gomes,et al.  Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. , 2011, Biochimica et biophysica acta.

[5]  Kenneth A. Jacobson,et al.  Behavioral Characterization of Mice Lacking the A3 Adenosine Receptor: Sensitivity to Hypoxic Neurodegeneration , 2003, Cellular and molecular neurobiology.

[6]  S. Lipton.  The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. , 2005, Current Alzheimer research.

[7]  D. Standaert,et al.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease. , 2004, Pharmacology & therapeutics.

[8]  Y. T. Wang,et al.  Microglial VEGF Receptor Response Is an Integral Chemotactic Component in Alzheimer's Disease Pathology , 2009, The Journal of Neuroscience.

[9]  B. Fredholm,et al.  Modulation of glial cell functions by adenosine receptors , 2007, Physiology & Behavior.

[10]  R. Lin,et al.  Right Thing at a Wrong Time?. Adenosine A3 Receptors and Cerebroprotection in Stroke , 2001, Annals of the New York Academy of Sciences.

[11]  H. Boddeke,et al.  LPS‐induced expression of a novel chemokine receptor (L‐CCR) in mouse glial cells in vitro and in vivo , 2003, Glia.

[12]  C. Limatola,et al.  Activity of Adenosine Receptors Type 1 Is Required for CX3CL1-Mediated Neuroprotection and Neuromodulation in Hippocampal Neurons1 , 2008, The Journal of Immunology.

[13]  T. Kita,et al.  Molecular Cloning of a Novel Scavenger Receptor for Oxidized Low Density Lipoprotein, SR-PSOX, on Macrophages* , 2000, The Journal of Biological Chemistry.

[14]  D. Soler,et al.  Expression Cloning of the STRL33/BONZO/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines , 2001, The Journal of Immunology.

[15]  P. Svenningsson,et al.  Adenosine and brain function. , 2005, International review of neurobiology.

[16]  D. Choi,et al.  The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. , 1990, Annual review of neuroscience.

[17]  Huangui Xiong,et al.  Chemokine CCL2 modulation of neuronal excitability and synaptic transmission in rat hippocampal slices , 2011, Journal of neurochemistry.

[18]  J. Kuo,et al.  Gliotoxic Action of Glutamate on Cultured Astrocytes , 2000, Journal of neurochemistry.

[19]  Geoffrey T. Manley,et al.  Involvement of aquaporin-4 in astroglial cell migration and glial scar formation , 2005, Journal of Cell Science.

[20]  J. Leza,et al.  Astrocyte-Derived MCP-1 Mediates Neuroprotective Effects of Noradrenaline , 2009, The Journal of Neuroscience.

[21]  J. Ribeiro,et al.  Modulation and metamodulation of synapses by adenosine , 2010, Acta physiologica.

[22]  B B Fredholm,et al.  Adenosine, an endogenous distress signal, modulates tissue damage and repair , 2007, Cell Death and Differentiation.

[23]  T. Dunwiddie,et al.  Activation of Hippocampal Adenosine A3 Receptors Produces a Desensitization of A1 Receptor-Mediated Responses in Rat Hippocampus , 1997, The Journal of Neuroscience.

[24]  G. Burnstock,et al.  Purinoceptors on Neuroglia , 2009, Molecular Neurobiology.

[25]  Wen-ping Zhang,et al.  HYPOXIA‐INDUCED ASTROCYTES PROMOTE THE MIGRATION OF NEURAL PROGENITOR CELLS VIA VASCULAR ENDOTHELIAL FACTOR, STEM CELL FACTOR, STROMAL‐DERIVED FACTOR‐1α AND MONOCYTE CHEMOATTRACTANT PROTEIN‐1 UPREGULATION IN VITRO , 2007, Clinical and experimental pharmacology & physiology.

[26]  C. Weber,et al.  Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. , 2007, Biochemical and biophysical research communications.

[27]  R. Bullock,et al.  Glutamate release and cerebral blood flow after severe human head injury. , 1996, Acta neurochirurgica. Supplement.

[28]  C. Petito,et al.  Gene expression profiles in microdissected neurons from human hippocampal subregions. , 2004, Brain research. Molecular brain research.

[29]  C. Weber,et al.  Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by α- and γ-secretases , 2007 .

[30]  K. Jacobson,et al.  A selective agonist affinity label for A3 adenosine receptors. , 1994, Biochemical and biophysical research communications.

[31]  W. Rostène,et al.  Chemokines: a new class of neuromodulator? , 2007, Nature Reviews Neuroscience.

[32]  A. IJzerman,et al.  Interleukin-6 Upregulates Neuronal Adenosine A1 Receptors: Implications for Neuromodulation and Neuroprotection , 2008, Neuropsychopharmacology.

[33]  Markus Schwaninger,et al.  Stimulation of Interleukin‐6 Secretion and Gene Transcription in Primary Astrocytes by Adenosine , 1997, Journal of neurochemistry.

[34]  K. Reiss,et al.  Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells , 2005, Journal of neurochemistry.

[35]  B. Fredholm,et al.  Adenosine A1 Receptors and Microglial Cells Mediate CX3CL1-Induced Protection of Hippocampal Neurons Against Glu-Induced Death , 2010, Neuropsychopharmacology.

[36]  M. Mack,et al.  Role of astrocytes and chemokine systems in acute TNFα induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-κB and Akt , 2008, Molecular and Cellular Neuroscience.

[37]  K. Jacobson,et al.  The effects of adenosine A3 receptor stimulation on seizures in mice. , 1995, European journal of pharmacology.

[38]  R. Cunha,et al.  Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors , 2001, Neurochemistry International.

[39]  W. Rostène,et al.  Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release , 2009, Neuroscience.

[40]  K. Jacobson,et al.  Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. , 1995, Journal of medicinal chemistry.

[41]  A. de Mendonça,et al.  Participation of adenosine receptors in neuroprotection. , 2003, Drug news & perspectives.

[42]  B. Fredholm,et al.  Adenosine signaling and function in glial cells , 2010, Cell Death and Differentiation.

[43]  Wei-Chao Huang,et al.  TGF-β1 blockade of microglial chemotaxis toward Aβ aggregates involves SMAD signaling and down-regulation of CCL5 , 2010, Journal of Neuroinflammation.

[44]  B. Brew,et al.  Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes , 2003, Glia.

[45]  P. Magistretti,et al.  The role of astroglia in neuroprotection , 2009, Dialogues in clinical neuroscience.

[46]  B. Fredholm,et al.  CX3CL1 Is Neuroprotective in Permanent Focal Cerebral Ischemia in Rodents , 2011, The Journal of Neuroscience.

[47]  R. Miller,et al.  Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Honghong Yao,et al.  Involvement of TRPC Channels in CCL2-Mediated Neuroprotection against Tat Toxicity , 2009, The Journal of Neuroscience.

[49]  E. Butcher,et al.  The Primate Lentiviral Receptor Bonzo/STRL33 Is Coordinately Regulated with CCR5 and Its Expression Pattern Is Conserved Between Human and Mouse1 , 2000, The Journal of Immunology.

[50]  Osamu Yoshie,et al.  Cutting Edge: Profile of Chemokine Receptor Expression on Human Plasma Cells Accounts for Their Efficient Recruitment to Target Tissues 1 , 2003, The Journal of Immunology.

[51]  Beverly H. Koller,et al.  Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.

[52]  A. Dávalos,et al.  Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. , 1996, Stroke.

[53]  Y. Sekino,et al.  Interleukin‐6‐type cytokines in neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A1 receptor function , 2010, Journal of neurochemistry.

[54]  R. Ransohoff,et al.  Selective Chemokine Receptor Usage by Central Nervous System Myeloid Cells in CCR2-Red Fluorescent Protein Knock-In Mice , 2010, PloS one.

[55]  K. Jacobson,et al.  Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. , 2007, Biochemical pharmacology.

[56]  G. Graham,et al.  Astrocytes modulate the chemokine network in a pathogen-specific manner. , 2010, Biochemical and biophysical research communications.

[57]  Sharon Engel,et al.  A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo , 2000, Nature Immunology.

[58]  Marcel M. Verbeek,et al.  CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement , 2006, Neuroscience Letters.

[59]  M. Ciotti,et al.  Development of a method for measuring cell number: application to CNS primary neuronal cultures. , 1994, Cytometry.

[60]  R. Ransohoff,et al.  Chemokines and chemokine receptors in neurological disease: Raise, retain, or reduce? , 2007, Neurotherapeutics.

[61]  G. Burnstock,et al.  Purinoceptors on Neuroglia , 2009, Molecular Neurobiology.

[62]  Hosung Jung,et al.  Chemokines and the pathophysiology of neuropathic pain , 2007, Proceedings of the National Academy of Sciences.

[63]  H. Winn,et al.  Role of Adenosine A2 Receptors in Regulation of Cerebral Blood Flow during Induced Hypotension , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  P. Ince,et al.  CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[65]  K. Nieber,et al.  Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons. , 2001, Neuropharmacology.

[66]  P. Conn,et al.  Protein Kinase C and A3 Adenosine Receptor Activation Inhibit Presynaptic Metabotropic Glutamate Receptor (mGluR) Function and Uncouple mGluRs from GTP-Binding Proteins , 1998, The Journal of Neuroscience.

[67]  K. Nieber,et al.  Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons , 2001, Neuropharmacology.

[68]  Yun Wang,et al.  Activation of adenosine A3 receptors reduces ischemic brain injury in rodents , 2006, Journal of neuroscience research.

[69]  R. Clark,et al.  To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways , 2003, Progress in Neurobiology.

[70]  F. Nicoletti,et al.  Activation of A1 adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S‐100β protein from cultured astrocytes , 1999, Glia.

[71]  H. Boddeke,et al.  Expression of L‐CCR in HEK 293 cells reveals functional responses to CCL2, CCL5, CCL7, and CCL8 , 2003, Journal of leukocyte biology.